

UNITED THERAPEUTICS CORP

Form 8-K

August 20, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 19, 2002

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

000-26301

52-1984749

(State or Other
Jurisdiction of
Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification Number)

1110 Spring Street
Silver Spring, MD

20910

Registrant's telephone number, including area code:

(301) 608-9292

Item 5. Other Events.

On August 19, 2002, United Therapeutics Corporation (the Company) issued a press release announcing that Dr. Martine A. Rothblatt, the Chairman and Chief Executive Officer of the Company, entered into a trading plan in compliance with Rule 10b5-1. A copy of the press release is attached hereto and incorporated herein by this reference.

Item 7. Exhibits

(c) Exhibits

Exhibit No	Description of Exhibit
99.1	Press release dated August 19, 2002.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: August 19, 2002

By: /s/ Paul A. Mahon

Name: Paul A. Mahon
Title: Senior V.P. and General Counsel

EXHIBIT INDEX

Exhibit No	Description of Exhibit
99.1	Press release dated August 19, 2002.